Journal
CARCINOGENESIS
Volume 31, Issue 10, Pages 1787-1793Publisher
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgq158
Keywords
-
Categories
Funding
- National Cancer Institute, National Institutes of Health [1R03CA137736-01]
- Center for Colon Cancer Research, National Center for Research Resources, National Institutes of Health [P20RR17698-01]
- Lipidomics Core at Medical University of South Carolina
- Center for Colon Cancer Research
- National Center for Research Resources
- National Institutes of Health
Ask authors/readers for more resources
Sphingolipid metabolism is driven by inflammatory cytokines. These cascade of events include the activation of sphingosine kinase (SK), and subsequent production of the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). Overall, S1P is one of the crucial components in inflammation, making SK an excellent target for the development of new anti-inflammatory drugs. We have recently shown that SK inhibitors suppress colitis and hypothesize here that the novel SK inhibitor, ABC294640, prevents the development of colon cancer. In an azoxymethane (AOM)/dextran sulfate sodium (DSS) mouse model, there was a dose-dependent decrease in tumor incidence with SK inhibitor treatment. The tumor incidence (number of animals with tumors per group) in the vehicle, ABC294640 (20 mg/kg) and ABC294640 (50 mg/kg) groups were 80, 40 and 30%, respectively. Tumor multiplicity (number of tumors per animal) also decreased from 2.1 +/- 0.23 tumors per animal in the AOM + DSS + vehicle group to 1.2 +/- 0 tumors per animal in the AOM + DSS + ABC294640 (20 mg/kg) and to 0.8 +/- 0.4 tumors per animal in the AOM + DSS + ABC294640 (50 mg/kg) group. Importantly, with ABC294640, there were no observed toxic side effects. To explore mechanisms, we isolated cells from the colon (CD45-, representing primarily colon epithelial cells) and (CD45+, representing primarily colon inflammatory cells) then measured known targets of SK that control cell survival. Results are consistent with the hypothesis that the inhibition of SK activity by our novel SK inhibitor modulates key pathways involved in cell survival and may be a viable treatment strategy for the chemoprevention colitis-driven colon cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available